SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
(Address of principal executive offices)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
As previously announced, on November 10, 2020, Merit Medical Systems, Inc. (the “Company”) will hold a conference call and live webcast to introduce its projections for growth over the next three fiscal years and answer questions from participants on the call. In connection with that call, the Company issued a press release regarding its new multi-year financial targets for the period 2020 to 2023, which will be discussed during the investor call. The Company’s press release provides information regarding access to the call and webcast. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In addition, on November 10, 2020, the Company has posted to its website the slide presentation that will be used during the call and webcast. A copy of the presentation is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The Company is furnishing the information in this Item 7.01 (including the referenced exhibits attached hereto) pursuant to Regulation FD promulgated under the Exchange Act. Such information shall not be deemed “filed” for purposes of the Exchange Act or otherwise subject to the liabilities of that section, and is not deemed incorporated by reference into any filing under the Securities Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL and incorporated as Exhibit 101
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MERIT MEDICAL SYSTEMS, INC.
Date: November 10, 2020
/s/ Brian G. Lloyd
Brian G. Lloyd
Chief Legal Officer and Corporate Secretary